Advertisement
Advertisement
MIST
Milestone Pharmaceuticals Inc. Common Shares
1.22
USDSponsored
+0.04
+3.39%
Aug 07, 15:59 UTC -4
Closed
Pre-Market
1.22
0.00
-0.41%
MIST Earnings Reports
Positive Surprise Ratio
MIST beat 16 of 28 last estimates.
57%
Next Report
In 2 Days
Date of Next Report
Aug 12, 2026
Estimate for Q2 26 (Revenue/ EPS)
$833.00K
/-$0.19
Implied change from Q1 26 (Revenue/ EPS)
+250.00%
/-5.00%
Implied change from Q2 25 (Revenue/ EPS)
--
/-5.00%
Milestone Pharmaceuticals Inc. Common Shares earnings per share and revenue
On May 13, 2026, MIST reported earnings of -0.20 USD per share (EPS) for Q1 26, missing the estimate of 0.31 USD, resulting in a -163.94% surprise. Revenue reached 238.00 thousand, compared to an expected 38.40 million, with a -99.38% difference. The market reacted with a -9.47% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of -0.19 USD, with revenue projected to reach 833.00 thousand USD, implying an decrease of -5.00% EPS, and increase of 250.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
REGENXBIO Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.05
Actual
$0.43
Surprise
+626.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
SAB Biotherapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.29
Actual
-$0.28
Surprise
+5.15%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
Genmab A/S ADS
Report Date
Aug 06, 2026 For Q2 26
Estimate
$3.59
Actual
$0.54
Surprise
-84.98%
Praxis Precision Medicines, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$3.73
Actual
-$2.87
Surprise
+23.14%
Halozyme Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.87
Actual
$2.27
Surprise
+21.75%
Cytokinetics Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.67
Actual
-$1.50
Surprise
+10.35%
FAQ
What were Milestone Pharmaceuticals Inc. Common Shares's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Milestone Pharmaceuticals Inc. Common Shares reported EPS of -$0.20, missing estimates by -163.94%, and revenue of $238.00K, -99.38% below expectations.
How did the market react to Milestone Pharmaceuticals Inc. Common Shares's Q1 2026 earnings?
The stock price moved down -9.47%, changed from $1.90 before the earnings release to $1.72 the day after.
When is Milestone Pharmaceuticals Inc. Common Shares expected to report next?
The next earning report is scheduled for Aug 12, 2026.
What are the forecasts for Milestone Pharmaceuticals Inc. Common Shares's next earnings report?
Based on 6
analysts, Milestone Pharmaceuticals Inc. Common Shares is expected to report EPS of -$0.19 and revenue of $833.00K for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement